Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

Dana Lukin, David Faleck, Ronghui Xu, Yiran Zhang, Aaron Weiss, Satimai Aniwan, Siri Kadire, Gloria Tran, Mahmoud Rahal, Adam Winters, Shreya Chablaney, Jenna L. Koliani-Pace, Joseph Meserve, James P. Campbell, Gursimran Kochhar, Matthew Bohm, Sashidhar Varma, Monika Fischer, Brigid Boland, Siddharth SinghRobert Hirten, Ryan Ungaro, Karen Lasch, Eugenia Shmidt, Vipul Jairath, David Hudesman, Shannon Chang, Arun Swaminath, Bo Shen, Sunanda Kane, Edward V. Loftus, Bruce E. Sands, Jean Frederic Colombel, Corey A. Siegel, William J. Sandborn, Parambir S. Dulai

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science